The existence of pathophysiological differences among the different mutant KRAS is further supported by clinical observations indicating that patients with mutant KRAS colorectal cancer may respond to targeted therapy depending on the type of point mutation they express [16]. This evidence concerns the gene KRAS and colorectal cancer.